Skip to content
Sudeep Pharma logo

Sudeep Pharma

SUDEEPPHRM NSE
₹1,116.70 No trade today
P/E
66.35
View as Markdown
MCP
Close 4 Nov 2026 ₹1,116.70 +342.55 +44.2% since 28 Nov 2025
Start ₹774.15

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
28.20%
Debt to Equity
0.17
EPS (TTM)
₹16.83
Book Value
₹84.76
Market Cap
—
P/E (TTM)
66.35
P/B
13.17
ROE
25.20%
Dividend Yield
0.14%
EBITDA
₹251 Cr
52W High
₹1,378.00
52W Low
₹524.05
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

Sudeep Pharma peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Sudeep Pharma (this company)
₹1,116.7066.35₹12,439 Cr13.170.14%25.20%28.20%₹676 Cr₹185 Cr
Median 8 companies₹1,587.7052.58₹1,25,337 Cr7.290.44%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

47 Average

Data confidence 98/100

Category scores

Quality
45
Weak
Returns, margins, earnings quality 22% weight
Valuation
16
Poor
Cheap vs sector & own history 24% weight
Growth
68
Strong
Sales & profit trajectory 9% weight
Financial Health
73
Strong
Solvency, leverage, coverage 9% weight
Momentum
85
Strong
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has delivered good profit growth of 39.0% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%

Weaknesses

1
  • Stock is trading at 12.7 times its book value

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3511
OscillatorsNeutral252
Moving AveragesStrong Bullish109

Key readings

RSI (14)
54.73
Neutral
MACD (12,26,9)
−5.65
Bullish
SMA (50)
1,134.83
Bearish
SMA (200)
830.65
Bullish

As of

Analyst Rating

Based on 2 analysts
TIED50%

0 of 2 analysts rate Buy, 1 Hold, 1 Sell.

As of

BUY
0
0%
HOLD
1
50%
SELL
1
50%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+24.46%
3Y+14.38%
1Y+27.89%
TTM+23.18%

Net profit

Net profit growth by window
5Y+39.45%
3Y+41.05%
1Y+25.18%
TTM+20.92%

Operating cash flow

Operating cash flow growth by window
5Y+14.87%
3Y+13.40%
1Y+42.86%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+14.27 pp
3Y+13.76 pp
1Y−3.51 pp
TTM−2.89 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹123 Cr
Mar 2021₹215 Cr
Mar 2022₹343 Cr
Mar 2023₹429 Cr
Mar 2024₹459 Cr
Mar 2025₹502 Cr
Mar 2026₹642 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020₹18.00 Cr
Mar 2021₹33.00 Cr
Mar 2022₹50.00 Cr
Mar 2023₹62.00 Cr
Mar 2024₹133 Cr
Mar 2025₹139 Cr
Mar 2026₹174 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹69.80 Cr −11.9% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 5 Oct 2026
AI opinion · based on fundamentals
Risk high

As of the 2026-10-05 close, Sudeep Pharma Ltd traded at ₹1,173.4, giving it a market capitalisation of ₹13,253.39 crore. At that price the stock was valued at 69.72x trailing earnings (EPS ₹16.83) and 15x book value. Its fundamentals are strong: 5-year profit CAGR of 39%, 3-year average ROE of 32%, ROCE of 24.22% and debt-to-equity of 0.17. Current ROE of 19.41% is well below its 3-year average, and 3-year sales growth of 14% is much slower than the 5-year rate of 24%.

Bull Case 7
  • Profit has compounded at 39% CAGR over 5 years and 40% CAGR over 3 years. Over both periods, earnings grew much faster than sales (24% and 14% respectively), which points to operating leverage or a shift toward higher-margin products.
  • Return ratios have been high. ROE averaged 32% over 3 and 5 years, and current ROCE is 24.22%, which suggests the business earns well on the capital it uses.
  • The balance sheet carries little debt. Debt-to-equity is 0.17, which limits financial risk and leaves room to borrow for future capex or acquisitions.
  • Growth has picked up again recently. TTM sales growth of 24% is well above the 3-year CAGR of 14%, and TTM profit growth is still 20%.
  • 5-year sales CAGR of 24% shows demand has held up over a longer period, beyond any single strong year.
  • The stock has shown strong momentum. At ₹1,173.4 on 2026-10-05, it was about 124% above its 52-week low of ₹524.05, which suggests the market has been warming to the story.
  • The stock was about 14.8% below its 52-week high of ₹1,378. Part of the earlier peak valuation had already come off as of 2026-10-05.
Bear Case 8
  • The valuation is demanding. A trailing P/E of 69.72x means an earnings yield of about 1.4%, so the price already assumes years of strong growth with little margin for error.
  • At 15x book value, the stock prices in high return ratios for a long time. That gap looks harder to justify with current ROE at 19.41%.
  • ROE has been falling. It was 32% on a 3-year basis, 25% last year and 19.41% currently, which could reflect a larger equity base, slower returns on new capital, or both.
  • Sales growth slowed over the medium term. The 3-year CAGR of 14% is well below the 5-year CAGR of 24%, which suggests growth has not been steady.
  • Profit is now growing slower than sales. TTM profit grew 20% against 24% sales growth, which may signal margin pressure after years of margin expansion.
  • The 52-week range of ₹524.05 to ₹1,378 shows a high of about 2.6x the low. That means the stock has been very volatile, with a risk of sharp drawdowns if sentiment turns.
  • Shareholder payouts are small. The dividend yield of 0.13% gives almost no income support at current prices, so returns depend almost entirely on growth.
  • There is no multi-year stock return history (1, 3 and 5-year stock CAGR data are not available), so there is little public-market track record to judge how the stock behaves across cycles.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

30d ago

TL;DR: The only recent news for Sudeep Pharma is routine investor outreach: plant visits in Gujarat on Sep 23-24 and the Nuvama Emerging India CEO Forum on Sep 28, 2026. These meetings show management is actively engaging institutional investors and may raise the stock's visibility, but they contain no financial or operational information that moves the fundamentals. No specific risks came up in this period, though the news flow is too thin to say whether the trend is improving or deteriorating. Watch for analyst commentary after the plant visits and the next quarterly results for clearer direction.

Neutral 2
  • Nuvama CEO Forum participation Sep 23

    Sudeep Pharma will take part in the Nuvama Emerging India CEO Forum 2026 in Mumbai on September 28, 2026. The company confirmed that no unpublished price sensitive information will be discussed.

  • Gujarat plant visit investor meet Sep 16

    Sudeep Pharma has scheduled analyst and institutional investor meetings in Gujarat on September 23-24, 2026, including plant visits.

Quarterly Results

₹ Cr
SUDEEPPHRM quarterly results, ₹ crore
Particulars Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
149
116
158
125
163
172
182
158
197
Expenses
85
76
99
81
107
112
120
103
123
Operating Profit
63
39
59
44
55
60
63
55
73
OPM %
43%
34%
37%
35%
34%
35%
34%
35%
37%
Other Income
2
2
4
5
10
7
6
5
6
Interest
1
1
2
2
2
1
2
2
3
Depreciation
3
3
3
3
4
4
4
4
5
PBT
62
38
58
44
60
62
63
54
71
Tax %
21%
24%
24%
29%
21%
23%
23%
25%
27%
Net Profit
49
29
44
31
47
48
49
41
52
EPS (₹)
5.8
2.95
4.54
3.17
4.71
4.2
4.33
3.59
—

Sep 2026: from the results filed on 28 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
SUDEEPPHRM profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
123
215
343
429
459
502
642
676
Expenses
98
171
276
338
276
310
419
443
Operating Profit
25
44
67
90
183
192
223
233
OPM %
21%
20%
20%
21%
40%
38%
35%
34%
Other Income
3
3
7
9
6
9
28.59
29
Interest
1
1
2
6
5
7
8
8
Depreciation
3
4
5
8
9
11
15
16
PBT
25
43
69
86
175
183
228
238
Tax %
27%
22%
27%
28%
24%
24%
24%
—
Net Profit
18
33
50
62
133
139
174
184
EPS (₹)
2.15
3.97
5.97
7.42
15.86
14.27
15.31
16.83
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
SUDEEPPHRM balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
1
1
1
1
1
10
11
Reserves
80
113
162
222
355
481
872
Borrowings
20
31
84
83
78
140
150
Other Liabilities
30
67
97
113
80
86
141
Total Liabilities
131
213
344
420
514
717
1,174
Fixed Assets
60
68
137
158
180
189
337
CWIP
8
24
8
26
45
88
185
Investments
6
19
0
3
0
0
0
Other Assets
57
102
199
232
289
439
652
Total Assets
131
213
344
420
514
717
1,174

Cash Flow

₹ Cr
SUDEEPPHRM cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
10
35
−3
48
66
49
70
Investing
−22
−40
−38
−50
−49
−79
−327
Financing
12
13
51
−10
−13
53
247
Net Cash Flow
0
8
10
−11
4
23
−10
Free Cash Flow
1
24
−77
1
13
−15
−49
CFO/EBITDA
62
104
22
78
60
47
56

Ratios

SUDEEPPHRM financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
90
94
114
80
115
135
129
Inventory Days
77
79
104
142
147
309
356
Days Payable
70
79
76
77
112
145
113
Cash Conversion Cycle
97
93
142
145
150
298
372
Working Capital Days
46
13
30
92
99
144
175
ROCE %
—
36%
36%
33%
49%
36%
28%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sudeep Pharma insights

64 extracted metrics across FY20–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 76.15%
  • DIIs 14.05%
  • Public 5.43%
  • FIIs 2.93%
  • Others 1.44%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Documents

Frequently Asked Questions about Sudeep Pharma

What does Sudeep Pharma Ltd do?
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.
Where is Sudeep Pharma Ltd (SUDEEPPHRM) listed?
Sudeep Pharma Ltd trades as SUDEEPPHRM on the NSE and under code 544619 on the BSE.
Which sector does Sudeep Pharma Ltd belong to?
Sudeep Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Sudeep Pharma Ltd?
Sudeep Pharma Ltd trades at a PE ratio of 66.35 as of 4 Nov 2026, on earnings per share of ₹16.83, against a book value of ₹84.76 per share.
What is the 52-week high and low of Sudeep Pharma Ltd?
Over the last 52 weeks Sudeep Pharma Ltd has traded between ₹524.05 and ₹1,378 as of 4 Nov 2026.
Does Sudeep Pharma Ltd pay dividends?
Sudeep Pharma Ltd has a dividend yield of 0.14%.
What is the Return on Equity (ROE) of Sudeep Pharma Ltd?
Sudeep Pharma Ltd reported a return on equity of 25.20%. Its debt-to-equity ratio is 0.17.

Company Information

Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.

Website sudeeppharma.com
Listed 28 Nov 2025
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUDEEPPHRM.md for Sudeep Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month